Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial
Hoogendoorn Martine, Al Maiwenn J., Beeh Kai-Michael, Bowles David, Graf von der Schulenburg J. Matthias, Lungershausen Juliane, Monz Brigitta U., Schmidt Hendrik, Vogelmeier Claus, Rutten-van Mölken Maureen P.M.H.
Source: Eur Respir J 2013; 41: 556-564
Disease area: Airway diseases
Abstract The aim of this study was to perform a 1-yr trial-based cost-effectiveness analysis (CEA) of tiotropium versus salmeterol followed by a 5-yr model-based CEA.The within-trial CEA, including 7,250 patients with moderate to very severe chronic obstructive pulmonary disease (COPD), was performed alongside the 1-yr international randomised controlled Prevention of Exacerbations with Tiotropium (POET)-COPD trial comparing tiotropium with salmeterol regarding the effect on exacerbations. Main end-points of the trial-based analysis were costs, number of exacerbations and exacerbation days. The model-based analysis was conducted to extrapolate results to 5 yrs and to calculate quality-adjusted life years (QALYs).1-yr costs per patient from the German statutory health insurance (SHI) perspective and the societal perspective were €126 (95% uncertainty interval (UI) €55–195) and €170 (95% UI €77–260) higher for tiotropium, respectively. The annual number of exacerbations was 0.064 (95% UI 0.010–0.118) lower for tiotropium, leading to a reduction in exacerbation-related costs of €87 (95% UI €19–157). The incremental cost-effectiveness ratio was €1,961 per exacerbation avoided from the SHI perspective and €2,647 from the societal perspective. In the model-based analyses, the 5-yr costs per QALY were €3,488 from the SHI perspective and €8,141 from the societal perspective.Tiotropium reduced exacerbations and exacerbation-related costs, but increased total costs. Tiotropium can be considered cost-effective as the resulting cost-effectiveness ratios were below commonly accepted willingness-to-pay thresholds.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hoogendoorn Martine, Al Maiwenn J., Beeh Kai-Michael, Bowles David, Graf von der Schulenburg J. Matthias, Lungershausen Juliane, Monz Brigitta U., Schmidt Hendrik, Vogelmeier Claus, Rutten-van Mölken Maureen P.M.H.. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J 2013; 41: 556-564
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002
Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Source: Eur Respir J 2010; 35: 79-87 Year: 2010
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Source: Eur Respir J 2004; 23: 241-249 Year: 2004
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Interval exercise for patients with severe COPD – randomised trial [SRCTN11611768] Source: Annual Congress 2006 - Organisation and programmes in pulmonary rehabilitation Year: 2006
Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Safety of tiotropium in patients with cardiac events in the UPLIFT® trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013